RxDoctor Payments Data

Caroline Segovia

Family · Hampton, VANPI 1083298780

Payments from drug & device makers

$4,756in general payments, 2019–2025

Across 28 payments — averaging $169.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacosmos Therapeutics Inc.$3K
  • E.r. Squibb & Sons, L.L.C.$456
  • Genentech USA, Inc.$249
  • Incyte Corporation$216
  • Takeda Pharmaceuticals U.S.A., Inc.$199
  • EMD Serono, Inc.$125
  • plus $811 from 10 others

What the payments were for

  • Speaking & faculty fees$1,76437%
  • Travel & lodging$62113%
  • Food & beverage$2,09744%
  • Education$2746%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,756 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$2,404
Medicare patients
27
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$45,180
JardianceEmpagliflozin19$21,665
OzempicSemaglutide17$16,096
JanuviaSitagliptin Phosphate11$15,113
Fluticasone-SalmeterolFluticasone Propion/Salmeterol97$8,582
Albuterol Sulfate HfaAlbuterol Sulfate264$5,957
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,858
Duloxetine Hcl73$2,862
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm13$2,685
Diclofenac Sodium139$2,503
Atorvastatin Calcium276$1,984
Rosuvastatin Calcium211$1,624
Gabapentin125$1,528
Fluticasone Propionate139$1,242
Metoprolol Succinate107$1,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$122$21,66519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.

Other family in Hampton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →